| Title: | Nonselective beta-adrenoceptor blocker use and risk of Parkinson's disease: from multiple real-world evidence |
| Journal: | BMC Medicine |
| Published: | 14 Nov 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37964359/ |
| DOI: | https://doi.org/10.1186/s12916-023-03122-z |
| URL: | https://bmcmedicine.biomedcentral.com/counter/pdf/10.1186/s12916-023-03122-z |
Publication 8328
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundPeople with hypertension have a higher risk of developing Parkinson's disease (PD), epidemiological evidence suggests that multiple antihypertensives may affect the occurrence and development of PD with inconsistent results. With multisource data, we sought to determine whether specific antihypertensive classes elevated or reduced the risk for PD.MethodsWe used a mixed methods approach that combines 4 methodologies. First, we conducted a disproportionality analysis using the reports causing adverse events in the US Food and Drug Administration Adverse Events Reporting System (FAERS) to explore the effect of different classes of antihypertensive medications on the risk of PD; based on the findings from FAERS, a meta-analysis and a UK Biobank cohort analysis were used to further assess the association of drug use with PD; finally, we employed Mendelian randomization (MR) analysis to validate the causal relationship between the drug target and the occurrence of PD.ResultsIn the disproportionality analysis using the FAERS (N = 187,266), nonselective beta-adrenoceptor blockers (NBBs) were demonstrated to have a significant association with PD (reporting odds ratio (ROR) = 3.13; 95% CI 2.33-4.22). In the meta-analysis of 12 studies with 12,183,809 participants, PD risk was elevated in NBBs (RR, 1.64; 95% CI, 1.19-2.09) when stratified by subtypes of BBs. Among the 105,763 participants included in the cohort analysis using data from the UK Biobank, individuals who used NBBs had a significantly increased risk of PD compared to nonusers (HR, 1.47; 95% CI 1.04-2.06). The MR analysis revealed a significant association between higher expression of the β2 adrenergic receptor (ADRB2) gene, a drug target blocked by NBBs, and a reduced risk of PD (OR, 0.85; 95% CI 0.73-0.99).ConclusionsOur comprehensive study indicated that regular NBB use is associated with an increased risk of PD. In light of the detrimental effects of NBBs on PD, some people should choose alternative antihypertensive treatments.</p>
10 Authors
- Zeying Feng
- Qiuping Zhao
- Jingjing Wu
- Yiping Yang
- Xinru Jia
- Junlong Ma
- Haibo Tang
- Hong Yuan
- Guoping Yang
- Yao Lu
1 Application
| Application ID | Title |
|---|---|
| 75283 | Modifiable pathways in sex-specific arterial stiffness: Mendelian randomization analysis |
Enabling scientific discoveries that improve human health